HKU Scholars Hub: Browsing DSpace

Browsing by Author Srimuninnimit, V

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 1 to 6 of 6

	Title	Author(s)	Issue Date	Views
	Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies Journal:Lung Cancer	Wu, YL Lee, VHF Liam, CK Lu, S Park, K Srimuninnimit, V Wang, J Zhou, CC Appius, A Button, P Hooper, G Palma, JF Schulze, K Scudder,, S Shames, DS Yin, AY Zhang, GL Mok, T	2018	75
	Efficacy and safety of every-2-weeks cetuximab combined with FOLFOX or FOLFIRI as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (mCRC): an Asia-Pacific nonrandomized phase II study (APEC) Proceeding/Conference:Journal of Clinical Oncology	Cheng, AL Cornelio, GH Shen, L Price, TJ Yang, TS Chung, IJ Dai, G Lin, JK Sharma, A Yeh, KH Ma, B Zaatar, A Guan, ZZ Masood, N Srimuninnimit, V Yau, TCC Sarholz, B Lim, RSC	2013	115
	Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study Journal:Clinical Colorectal Cancer	Cheng, AL Cornelio, G Shen, L Price, T Yang, TS Chung, IJ Dai, GH Lin, JK Sharma, A Yeh, KH Ma, B Zaatar, A Guan, Z Masood, N Srimuninnimit, V Yau, TCC Gibbs, P Wang, X Doval, DC Seung-Taek, O Shim, BY Gorospe, C Wang, HM Sirachainan, E Hill, A Suh, KW Beier, F Chatterjee, S Lim, R	2017	94
	Estimating The Magnitude Of Trastuzumab Effects Within Patient Subgroups In The Hera Trial Journal:Annals of Oncology	Untch, M Gelber, RD Jackisch, C Procter, M Baselga, J Bell, R Cameron, D Bari, M Smith, I Leyland-Jones, B de Azambuja, E Wermuth, P Khasanov, R Feng-yi, F Constantin, C Mayordomo, JI Su, CH Yu, SY Lluch, A Senkus-Konefka, E Price, C Haslbauer, F Sahui, TS Srimuninnimit, V Colleoni, M Coates, AS Piccart-Gebhart, MJ Goldhirsch, A Kwong, A	2008	68
	Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-lung cancer (FASTACT-2): a randomised, double-blind trial Journal:Lancet Oncology	Wu, YL Lee, JS Thongprasert, S Yu, CJ Zhang, L Ladrera, G Srimuninnimit, V Sriuranpong, V Sandoval-Tan, J Zhu, Y Liao, M Zhou, C Pan, H Lee, VHF Chen, YM Sun, Y Margono, B Fuerte, F Chang, GC Seetalarom, K Wang, J Cheng, CK Syahruddin, E Qian, X Ho, JCM Kurnianda, J Liu, HE Jin, K Truman, M Bara, I Mok, T	2013	125
	A randomized placebo-controlled phase III study of intercalated erlotinib with gemcitabine/platinum in first-line advanced non-small cell lung cancer (NSCLC): FASTACT-II Proceeding/Conference:Journal of Clinical Oncology	Mok, T Wu, YL Thongprasert, S Yu, CJ Zhang, L Ladrera, GE Srimuninnimit, V Sriuranpong, V Sandoval-Tan, J Zhu, Y Liao, M Zhou, C Pan, H Lee, V Chen, YM Sun, Y Margono, B Jin, K Truman, M Lee, JS	2012	164

Showing results 1 to 6 of 6